Biotechnology company Cereno Scientific (Nasdaq First North:CRNO B) announced on Friday that the first patient has been dosed with CS1 under its Expanded Access Program (EAP) for Pulmonary Arterial Hypertension (PAH).

This program allows patients who completed the Phase II trial to continue receiving CS1 based on perceived benefit, as determined by both the patient and physician.

The EAP aims to gather extensive data on long-term CS1 usage, supporting future regulatory discussions and pivotal trial planning. Approved since January 30, 2024, the EAP is an extension of the Phase II trial under an FDA protocol.

CS1, an HDAC inhibitor targeting PAH, has shown potential in Phase II trials, with topline results expected in Q3 2024.